Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Alendronate and atrial fibrillation.

Cummings SR, Schwartz AV, Black DM.

N Engl J Med. 2007 May 3;356(18):1895-6. No abstract available.

2.

Yearly zoledronic acid in postmenopausal osteoporosis.

Karam R, Camm J, McClung M.

N Engl J Med. 2007 Aug 16;357(7):712-3; author reply 714-5. No abstract available.

PMID:
17703529
3.

[Osteoporosis and bisphosphonates].

Zuber MA.

Z Rheumatol. 2007 Dec;66(8):713-5. German. No abstract available.

PMID:
17955251
4.

[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

Ringe JD.

MMW Fortschr Med. 2009 Mar 5;151(10):7. German. No abstract available.

PMID:
19472655
5.

Yearly zoledronic acid in postmenopausal osteoporosis.

Poole KE, Kaptoge S, Reeve J.

N Engl J Med. 2007 Aug 16;357(7):711-2; author reply 714-5. No abstract available.

PMID:
17703530
6.

Yearly zoledronic acid in postmenopausal osteoporosis.

de Nijs RN, Westgeest AA.

N Engl J Med. 2007 Aug 16;357(7):711; author reply 714-5. No abstract available.

7.

Bisphosphonates and atrial fibrillation.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):161. No abstract available.

PMID:
19492493
8.

Considering competing risks . . . Not all black and white.

Cauley JA, Ensrud KE.

Arch Intern Med. 2008 Apr 28;168(8):793-5. doi: 10.1001/archinte.168.8.793. No abstract available.

PMID:
18443252
9.

Yearly zoledronic acid in postmenopausal osteoporosis.

Chang JT.

N Engl J Med. 2007 Aug 16;357(7):713-4; author reply 714-5. No abstract available.

PMID:
17703528
10.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
11.

A once-yearly IV bisphosphonate for osteoporosis.

[No authors listed]

Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90. No abstract available.

PMID:
17975523
12.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
13.

What's the story with Fosamax? Recent reports have women wondering if they should stop taking this widely prescribed osteoporosis drug.

[No authors listed]

Harv Womens Health Watch. 2008 Nov;16(3):1-2. No abstract available.

PMID:
19043857
14.

Alendronate, osteoporosis, and atherosclerosis.

Strandberg TE.

Arch Intern Med. 2008 Nov 24;168(21):2386-7; author reply 2387. doi: 10.1001/archinte.168.21.2386-c. No abstract available.

PMID:
19029508
15.

[Osteoporotic fracture in menopausal women: alendronate reduces the risk].

Bize R, Lamy O, Peytremann-Bridevaux I.

Rev Med Suisse. 2008 Dec 10;4(183):2703. French. No abstract available.

PMID:
19157286
16.

Bisphosphonates and the risk of atrial fibrillation.

Sewerynek E, Stuss M.

Endokrynol Pol. 2011 Jan-Feb;62(1):93-6. Review.

17.

Oral bisphosphonates and atrial fibrillation.

Majumdar SR.

BMJ. 2008 Apr 12;336(7648):784-5. doi: 10.1136/bmj.39513.481065.80. Epub 2008 Mar 11. No abstract available.

18.

Evolving data about subtrochanteric fractures and bisphosphonates.

Shane E.

N Engl J Med. 2010 May 13;362(19):1825-7. doi: 10.1056/NEJMe1003064. Epub 2010 Mar 24. No abstract available.

PMID:
20335574
19.

Use of alendronate and risk of incident atrial fibrillation in women.

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM.

Arch Intern Med. 2008 Apr 28;168(8):826-31. doi: 10.1001/archinte.168.8.826.

PMID:
18443257
20.

[When should bisphosphonate treatment be discontinued?].

Eriksen EF, Halse J.

Tidsskr Nor Laegeforen. 2012 Aug 7;132(14):1630-2. doi: 10.4045/tidsskr.11.0788. Norwegian. No abstract available.

Supplemental Content

Support Center